Published in Br J Clin Pharmacol on November 23, 2015
Therapeutics in clinical toxicology: in the absence of strong evidence how do we choose between antidotes, supportive care and masterful inactivity. Br J Clin Pharmacol (2016) 0.84
Outcomes from massive paracetamol overdose: a retrospective observational study. Br J Clin Pharmacol (2016) 0.80
The 100 most influential publications in paracetamol poisoning treatment: a bibliometric analysis of human studies. Springerplus (2016) 0.78
Should we treat very large paracetamol overdose differently? Br J Clin Pharmacol (2017) 0.75
Who gets antidotes? choosing the chosen few. Br J Clin Pharmacol (2016) 0.75
N-Acetyl-L-cysteine and Cysteamine: New Strategies Against Mixed Biofilms of Non-encapsulated Streptococcus pneumoniae and Non-typeable Haemophilus influenzae. Antimicrob Agents Chemother (2016) 0.75
Sodium 4-phenylbutyric acid prevents murine acetaminophen hepatotoxicity by minimizing endoplasmic reticulum stress. J Gastroenterol (2016) 0.75
Pharmacokinetic modelling of modified acetylcysteine infusion regimens used in the treatment of paracetamol poisoning. Eur J Clin Pharmacol (2017) 0.75
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. Br Med J (1979) 6.45
Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Engl J Med (1988) 5.38
Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther (1973) 5.23
The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med (2005) 4.63
Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med (2009) 3.67
Cysteamine, methionine, and penicillamine in the treatment of paracetamol poisoning. Lancet (1976) 3.41
Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet (2013) 3.12
Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet (1977) 3.00
Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther (1974) 2.62
Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Ann Pharmacother (2008) 2.44
Identification of patients at risk of anaphylactoid reactions to N-acetylcysteine in the treatment of paracetamol overdose. Clin Toxicol (Phila) (2013) 2.13
Controlled trial of cysteamine in treatment of acute paracetamol (acetaminophen) poisoning. Lancet (1976) 1.97
Kinetics and metabolism of paracetamol and phenacetin. Br J Clin Pharmacol (1980) 1.87
Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med (1991) 1.82
A multicenter comparison of the safety of oral versus intravenous acetylcysteine for treatment of acetaminophen overdose. Clin Toxicol (Phila) (2010) 1.68
A dosing regimen for immediate N-acetylcysteine treatment for acute paracetamol overdose. Clin Toxicol (Phila) (2011) 1.66
Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. Acad Emerg Med (2008) 1.66
Oral and Intravenous Acetylcysteine for Treatment of Acetaminophen Toxicity: A Systematic Review and Meta-analysis. West J Emerg Med (2013) 1.52
Safety and efficacy of intravenous N-acetylcysteine for acetaminophen overdose: analysis of the Hunter Area Toxicology Service (HATS) database. Curr Med Res Opin (2007) 1.48
Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol (1988) 1.46
The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol (1989) 1.30
Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol (1998) 1.26
Adverse reactions to acetylcysteine and effects of overdose. Br Med J (Clin Res Ed) (1984) 1.26
Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med (2000) 1.25
Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) (2009) 1.22
Effect of the UK's revised paracetamol poisoning management guidelines on admissions, adverse reactions and costs of treatment. Br J Clin Pharmacol (2014) 1.22
Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning. Br J Clin Pharmacol (2001) 1.18
Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high acetaminophen concentrations after overdose. Clin Toxicol (Phila) (2008) 1.11
The value of plasma acetaminophen half-life in antidote-treated acetaminophen overdosage. Clin Pharmacol Ther (2002) 1.10
Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Ann Pharmacother (2008) 1.07
Methionine and cysteamine in paracetamol (acetaminophen) overdose, prospective controlled trial of early therapy. J Int Med Res (1981) 1.05
Acetaminophen hepatotoxicity: an updated review. Arch Toxicol (2014) 1.04
Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin Toxicol (Phila) (2008) 1.04
Evaluation of a simplified N-acetylcysteine dosing regimen for the treatment of acetaminophen toxicity. Ann Pharmacother (2011) 1.01
Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study. Accid Emerg Nurs (2004) 0.99
Acetaminophen and acetylcysteine dose and duration: past, present and future. Clin Toxicol (Phila) (2012) 0.97
Pharmacokinetics of intravenous N-acetylcysteine in men at rest and during exercise. Eur J Clin Pharmacol (2004) 0.94
Adverse reactions to N-acetylcysteine. Hum Toxicol (1984) 0.92
Scottish and Newcastle antiemetic pre-treatment for paracetamol poisoning study (SNAP). BMC Pharmacol Toxicol (2013) 0.90
Evaluation of an Alternative Intravenous N-Acetylcysteine Regimen in Pediatric Patients. J Pediatr Pharmacol Ther (2015) 0.88
Bactrian ("double hump") acetaminophen pharmacokinetics: a case series and review of the literature. J Med Toxicol (2010) 0.88
Treatment of advanced malignancies with high-dose acetaminophen and N-acetylcysteine rescue. Cancer Invest (1996) 0.86
A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clin Toxicol (Phila) (2014) 0.86
Incidence and management of N-acetylcysteine-related anaphylactoid reactions during the management of acute paracetamol overdose. Eur J Emerg Med (2014) 0.83
Target biomarker profile for the clinical management of paracetamol overdose. Br J Clin Pharmacol (2015) 0.82
Hepatic failure despite early acetylcysteine following large acetaminophen-diphenhydramine overdose. Pediatrics (2011) 0.81
Using 0.45% saline solution and a modified dosing regimen for infusing N-acetylcysteine in children with paracetamol poisoning. Emerg Med Australas (2011) 0.81
Paracetamol poisoning: beyond the nomogram. Br J Clin Pharmacol (2015) 0.81
Effects of delay in infusion of N-acetylcysteine on appearance of adverse drug reactions after acetaminophen overdose: a retrospective study. Pharmacoepidemiol Drug Saf (2010) 0.80
Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther (2013) 0.80
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Vomiting in paracetamol overdose. Emerg Med J (2002) 0.77
Epidemiology, management and outcome of paracetamol poisoning in an inner city emergency department. Emerg Med J (2013) 0.76
Treatment of paracetamol overdose--authors' reply. Lancet (2014) 0.76
The Influence of Patient Characteristics on Anticholinergic Events in Older People. Dement Geriatr Cogn Dis Extra (2016) 0.82
Evaluation of Approaches to Deal with Low-Frequency Nuisance Covariates in Population Pharmacokinetic Analyses. AAPS J (2015) 0.78
An In Silico Knockout Model for Gastrointestinal Absorption Using a Systems Pharmacology Approach - Development and Application for Ketones. PLoS One (2016) 0.78
Population pharmacokinetics of intramuscular droperidol in acutely agitated patients. Br J Clin Pharmacol (2016) 0.75
Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin. Pharm Res (2015) 0.75
A general empirical model for renal drug handling in pharmacokinetic analyses. Br J Clin Pharmacol (2017) 0.75
Exploring inductive linearization for pharmacokinetic-pharmacodynamic systems of nonlinear ordinary differential equations. J Pharmacokinet Pharmacodyn (2017) 0.75
Lack of effect of tart cherry concentrate dose on serum urate in people with gout. Rheumatology (Oxford) (2020) 0.75
Simplification of a pharmacokinetic model for red blood cell methotrexate disposition. Eur J Clin Pharmacol (2015) 0.75
Selection and Qualification of Simplified QSP Models When Using Model Order Reduction Techniques. AAPS J (2017) 0.75
Evaluation of designs for renal drug studies based on the EMA and FDA guidelines for drugs that are predominantly secreted. Br J Clin Pharmacol (2020) 0.75